CTLA4 and hepatocellular carcinoma: An antitumor immunotherapy using anti-programmed death protein-1 (PD-1) and cytotoxic T lymphocyte antigen-4 (CTLA-4) antibodies demonstrated promising therapeutic effects for advanced HCC [21].